Staehli Wiser Anna, Dunning James, Charlebois Casey, Bliton Paul, Mourad Firas
Redington Fairview General Hospital, Skowhegan, ME 04976, USA.
American Academy of Manipulative Therapy Fellowship in Orthopaedic Manual Physical Therapy, Montgomery, AL 36104, USA.
J Clin Med. 2023 Aug 31;12(17):5678. doi: 10.3390/jcm12175678.
Carpometacarpal (CMC) osteoarthritis (OA) of the thumb is a painful condition that affects over 15% of individuals above the age of 30 and up to 30% of post-menopausal women. Dry needling (DN) has been found to reduce pain and disability in a variety of neuromusculoskeletal conditions; however, DN in the management of CMC OA has not been well studied.
Consecutive patients with clinical and radiographic evidence of CMC OA were treated with DN. The primary outcome measure was pain using the Numerical Pain Rating Scale (NPRS) at 12 weeks. Secondary outcome measures were the Upper Extremity Functional Index (UEFI-20) and the Global Rating of Change (GROC) scale. Outcome measures were collected at baseline, 4 weeks, 8 weeks, and 12 weeks.
Nine patients were treated for six sessions of periosteal DN over 3 weeks. Compared to baseline, statistically significant and clinically meaningful improvements were observed in thumb pain (NPRS mean difference: 2.6; = 0.029) and function (UEFI-20 mean difference: 21.3; = 0.012) at 12 weeks.
Statistically significant and clinically meaningful within-group improvements in thumb pain and function were observed at 12 weeks following six sessions of periosteal DN treatment. DN may be a useful intervention in the management of patients with CMC OA of the thumb.
拇指腕掌关节(CMC)骨关节炎(OA)是一种疼痛性疾病,影响超过15%的30岁以上人群以及高达30%的绝经后女性。干针疗法(DN)已被发现可减轻多种神经肌肉骨骼疾病的疼痛和功能障碍;然而,干针疗法在CMC OA治疗中的应用尚未得到充分研究。
对具有CMC OA临床和影像学证据的连续患者进行干针治疗。主要结局指标是12周时使用数字疼痛评分量表(NPRS)评估的疼痛程度。次要结局指标是上肢功能指数(UEFI-20)和整体变化评分(GROC)量表。在基线、4周、8周和12周时收集结局指标数据。
9例患者在3周内接受了6次骨膜干针治疗。与基线相比,12周时拇指疼痛(NPRS平均差异:2.6;P = 0.029)和功能(UEFI-20平均差异:21.3;P = 0.012)有统计学意义且具有临床意义的改善。
在进行6次骨膜干针治疗后的12周,观察到拇指疼痛和功能在组内有统计学意义且具有临床意义的改善。干针疗法可能是治疗拇指CMC OA患者的一种有效干预措施。